Can Fite Biopharma Ltd Net Asset Quality Index
Can Fite Biopharma Ltd net asset quality index. Can Fite Biopharma Ltd (CANF) has a Net Asset Quality Index of 58.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of ILA9.51 Million minus total liabilities of ILA3.92 Million yields net assets of ILA5.59 Million. A higher index indicates a stronger, lower-leverage balance sheet. Explore Can Fite Biopharma Ltd cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Can Fite Biopharma Ltd (2003–2025)
Net asset quality index of Can Fite Biopharma Ltd from 2003 to 2025. This chart shows how Can Fite Biopharma Ltd's Net Asset Quality Index has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the index stands at 58.8%, representing net assets of ILA5.59 Million against total assets of ILA9.51 Million ILA. See CANF book value for net asset value and shareholders' equity analysis.
Can Fite Biopharma Ltd Net Asset Quality Index by Year (2003–2025)
Can Fite Biopharma Ltd net asset quality index by year from 2003 to 2025. The table below presents the year-by-year Net Asset Quality Index for Can Fite Biopharma Ltd from 2003 to 2025, covering 23 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Can Fite Biopharma Ltd market capitalisation.
| Year | Quality Index | Net Assets (ILA) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 58.8% | ILA5.59 Million | ILA9.52 Million | ILA3.92 Million | ▼ -0.8 pp |
| 2024 | 59.6% | ILA5.44 Million | ILA9.12 Million | ILA3.68 Million | ▼ -2.9 pp |
| 2023 | 62.5% | ILA6.24 Million | ILA9.99 Million | ILA3.75 Million | ▲ +14.3 pp |
| 2022 | 48.2% | ILA4.47 Million | ILA9.28 Million | ILA4.81 Million | ▼ -22.8 pp |
| 2021 | 71.0% | ILA14.38 Million | ILA20.25 Million | ILA5.87 Million | ▲ +7.2 pp |
| 2020 | 63.8% | ILA6.07 Million | ILA9.52 Million | ILA3.45 Million | ▲ +33.9 pp |
| 2019 | 29.9% | ILA2.44 Million | ILA8.17 Million | ILA5.73 Million | ▼ -8.0 pp |
| 2018 | 37.9% | ILA3.02 Million | ILA7.95 Million | ILA4.94 Million | ▼ -1.1 pp |
| 2017 | 39.0% | ILA3.05 Million | ILA7.83 Million | ILA4.78 Million | ▲ +0.9 pp |
| 2016 | 38.1% | ILA3.87 Million | ILA10.17 Million | ILA6.29 Million | ▼ -21.2 pp |
| 2015 | 59.3% | ILA10.44 Million | ILA17.60 Million | ILA7.16 Million | ▼ -8.0 pp |
| 2014 | 67.3% | ILA6.86 Million | ILA10.19 Million | ILA3.33 Million | ▲ +0.1 pp |
| 2013 | 67.2% | ILA4.46 Million | ILA6.63 Million | ILA2.18 Million | ▲ +110.5 pp |
| 2012 | -43.3% | ILA-707.99K | ILA1.64 Million | ILA2.34 Million | ▼ -110.4 pp |
| 2011 | 67.1% | ILA3.29 Million | ILA4.90 Million | ILA1.61 Million | ▼ -3.4 pp |
| 2010 | 70.5% | ILA13.07 Million | ILA18.55 Million | ILA5.47 Million | ▲ +3.4 pp |
| 2009 | 67.1% | ILA13.49 Million | ILA20.10 Million | ILA6.62 Million | ▼ -0.6 pp |
| 2008 | 67.7% | ILA14.79 Million | ILA21.86 Million | ILA7.07 Million | ▼ -11.4 pp |
| 2007 | 79.1% | ILA38.70 Million | ILA48.94 Million | ILA10.23 Million | ▼ -12.7 pp |
| 2006 | 91.8% | ILA38.34 Million | ILA41.76 Million | ILA3.42 Million | ▼ -4.8 pp |
| 2005 | 96.6% | ILA35.83 Million | ILA37.09 Million | ILA1.26 Million | ▲ +237.8 pp |
| 2004 | -141.2% | ILA-1.81 Million | ILA1.28 Million | ILA3.09 Million | ▼ -217.5 pp |
| 2003 | 76.3% | ILA2.07 Million | ILA2.71 Million | ILA642.00K | — |